Onkologie. 2023:17(5):373-378 | DOI: 10.36290/xon.2023.070

Management of adverse reactions during treatment of anal cancer

Alžběta Hlodáková, Ondřej Kubeček, Jindřich Kopecký
Klinika onkologie a radioterapie, LF a FN Hradec Králové

Squamous cell carcinoma of the anus is a rare gastrointestinal tract disease. Due to the early presence of symptoms, which include bleeding, soreness and a feeling of resistance in the anus, this disease is usually diagnosed in its initial stages. The standard treatment consists of a multimodal approach combining radiotherapy and 5-fluorouracil-based chemotherapy with mitomycin or cisplatin. The prognosis is very favorable for most patients with the disease localized only to the anus, yet there are some risks associated with the treatment. This case report describes the management of a wide range of complications, including 5-fluorouracil-associated cardiotoxicity, development of heparin-induced thrombocytopenia, and thrombotic complications in a patient otherwise standardly treated for squamous cell carcinoma of the anus.

Keywords: squamous cell carcinoma of the anus, 5-fluorouracil cardiotoxicity, heparin-induced thrombocytopenia, thrombosis.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hlodáková A, Kubeček O, Kopecký J. Management of adverse reactions during treatment of anal cancer. Onkologie. 2023;17(5):373-378. doi: 10.36290/xon.2023.070.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cancer Stat Facts: Anal Cancer. [cited 2023 22.5.2023]; Available from: https://seer.cancer.gov/statfacts/html/anus.html.
    2. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101(2):281-288. Go to original source... Go to PubMed...
    3. Truelsen CG, Serup-Hansen E, Storm KS, et al. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study. Cancer Med. 2021;10(10):3224-3230. Go to original source... Go to PubMed...
    4. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama. 2008;299(16):1914-1921. Go to original source... Go to PubMed...
    5. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516-524. Go to original source... Go to PubMed...
    6. Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32(9):1087-1100. Go to original source... Go to PubMed...
    7. Chintala L, Vaka S, Baranda J, et al. Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now? Oncology Reviews. 2011;5(2):129-140. Go to original source...
    8. Faheem B, Kania B, Ashkar H, et al. 5-Fluorouracil-related Cardiotoxicity with Coronary Vasospasms. J Community Hosp Intern Med Perspect. 2022;12(5):71-74. Go to original source... Go to PubMed...
    9. Chong JH and Ghosh AK Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions. Interv Cardiol. 2019;14(2):89-94.
    10. Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. Go to original source... Go to PubMed...
    11. Sorrentino MF, Kim J, Foderaro AE, et al. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19(5):453-458. Go to original source... Go to PubMed...
    12. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2020;42(14):1289-1367. Go to original source... Go to PubMed...
    13. Schwartz BG, Economides C, Mayeda GS, et al. The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. Int J Impot Res. 2010;22(2):77-90. Go to original source... Go to PubMed...
    14. Streiff MB. Thrombosis in the setting of cancer. Hematology. 2016;(1):196-205. Go to original source... Go to PubMed...
    15. Fernandes CJ, Morinaga LTK, Alves JLJ, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev. 2019;28(151). Go to original source... Go to PubMed...
    16. Barbosa M. What is the Best Treatment for a Cancer Patient with Thrombosis? Clin Med Insights Oncol. 2014;8:49-55. Go to original source... Go to PubMed...
    17. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907. Go to original source... Go to PubMed...
    18. Tesařová P, Karetová D, Hirmerová J, et al. Prevence, diagnostika a léčba trombózy spojené se zhoubným nádorem. Transfuze a hematologie dnes. 2023;29(1):61-67. Go to original source...
    19. Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639. Go to original source... Go to PubMed...
    20. Kamposioras K, Mauri D, Papadimitriou K, et al. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth. Front Oncol. 2020;10:575148. Go to original source... Go to PubMed...
    21. Rucinska M, Nawrocki S. COVID-19 Pandemic: Impact on Cancer Patients. Int J Environ Res Public Health. 2022;19(19). Go to original source... Go to PubMed...
    22. Mauri D, Kamposioras K, Tsali L, et al. COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. Rev Recent Clin Trials. 2022;17(1):11-14. Go to original source... Go to PubMed...
    23. Kuter DJ. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica. 2022;107(6):1243-1263. Go to original source... Go to PubMed...
    24. Daviet F, Rouby F, Poullin P, et al. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019;85(2):403-412. Go to original source... Go to PubMed...
    25. Iba T, Watanabe E, Umemura Y, et al. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care. 2019;7:32. Go to original source... Go to PubMed...
    26. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med. 2008;14(6):648-655. Go to original source... Go to PubMed...
    27. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575-582. Go to original source... Go to PubMed...
    28. Gallo T, Curry SC, Padilla-Jones A, et al. A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk. J Thromb Haemost. 2019;17(2):383-388. Go to original source... Go to PubMed...
    29. Opatrny L, Warner MN. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol. 2004;76(3):240-4. Go to original source... Go to PubMed...
    30. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003;2(2):148-157. Go to original source...
    31. Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.